Dianthus Therapeutics, Inc. /DE/ Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO total compensation $10.61M; PEO compensation actually paid $16.74M; Other NEO average total compensation $5.15M.
- 2024-12-31: PEO total compensation $8.84M; PEO compensation actually paid $12.03M; Other NEO average total compensation $4.02M.
- 2023-12-31: PEO total compensation $496.02K; PEO compensation actually paid $343.58K; Other NEO average total compensation $841.81K.
- 2024-12-31: PEO total compensation $8.84M; PEO compensation actually paid $12.03M; Other NEO average total compensation $4.02M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|
| 2025-12-31 | | $10.61M | $16.74M | $5.15M | $8.04M | $652.06 | | -$162.34M | | 2026-04-09 |
|---|
| 2024-12-31 | | $8.84M | $12.03M | $4.02M | $4.95M | $344.94 | | -$84.97M | | 2026-04-09 |
|---|
| 2023-12-31 | | $496.02K | $343.58K | $841.81K | $794.74K | $164.56 | | -$43.55M | | 2026-04-09 |
|---|
| 2024-12-31 | | $8.84M | $12.03M | $4.02M | $4.95M | $30.76 | | -$84.97M | | 2025-04-10 |
|---|
| 2023-12-31 | | $496.02K | $343.58K | $841.81K | $794.74K | $14.67 | | -$43.55M | | 2025-04-10 |
|---|
| 2022-12-31 | | $1.65M | $3.78K | $1.07M | $24.77K | $8.92 | | -$28.48M | | 2025-04-10 |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|